Hyperlipidemia patients with long-term statin treatment are associated with a reduced risk of progression of benign prostatic enlargement

To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan's National Health Insurance Research Database, were divided into four statin cohorts (...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2020-12, Vol.23 (5), p.354-361
Main Authors: Shih, Hung-Jen, Tsai, Pei-Shan, Wen, Yu-Ching, Kao, Ming-Chang, Fan, Yen-Chun, Huang, Chun-Jen
Format: Article
Language:English
Subjects:
Aging
benign prostate enlargement
Cardiovascular disease
Cohort Studies
Health risks
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hyperlipidemia
Hyperlipidemias - drug therapy
Male
Mens health
Pathogenesis
progression
Proportional Hazards Models
Prostate
Prostatic Hyperplasia - drug therapy
Statin
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the impacts of statin treatment on the risk of benign prostatic enlargement (BPE) progression in hyperlipidemia patients. Newly diagnosed hyperlipidemia patients (n = 7961), identified from Taiwan's National Health Insurance Research Database, were divided into four statin cohorts (statin use >365 days, n = 1604; statin use 181-365 days, n = 813; statin use 91-180 days, n = 739; and statin use 31-90 days, n = 713) and one control cohort (cohort that used no statins, n = 4092). Study endpoint was occurrence of BPE progression (BPE diagnosis plus receiving BPE-related medications or surgery). Relative risks of BPE progression in the statin cohorts compared to the control cohort were analyzed. Multivariable Cox proportional hazards regression analyses demonstrated that BPE progression risk in the cohort used statins for >365 days was significantly lower than the control cohort (adjusted hazard ratio: 0.70, 95% confidence interval: 0.58 ∼ 0.85, p 
ISSN:1368-5538
1473-0790
DOI:10.1080/13685538.2018.1487392